ArticleFrontiers in oncology2025
Predictive significance of
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: anJournal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of pertinent metabolic parameters of Materials and methods: The data was retrospectively acquired from 105 patients who had been pathologically diagnosed gastric cancer prior to treatment at our institution, including clinical data, laboratory test results, histological information, Results: Among the 105 patients, 27 exhibited positive HER2 expression, while 78 demonstrated negative HER2 expression. Significant differences in MTV and TLG between patients exhibiting positive and negative HER2 expression ( Conclusions: The negative correlations between MTV/TLG and HER2 status demonstrated that HER2-positive tumors are associated with reduced metabolic burden, providing imaging biomarkers for clinical prognostic assessment. Notably, subgroup analysis in gastric adenocarcinoma and Lauren classification subgroups revealed significant negative associations between MTV and HER2 positivity, highlighting MTV's potential utility in predicting HER2 expression across histological subtypes of gastric cancer and supporting its role in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.